GlassScriptPhysician profile
German Treyger
NPI 1487002119
$74,852.81
in general payments reported to CMS, 2019-2025
37 companies · $38K in 2025
The $38K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,382 · 2020: $872 · 2021: $2,764 · 2022: $3,790 · 2023: $3,533 · 2024: $24K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $12K · Travel and Lodging: $3,678 · Education: $516 · Honoraria: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,500.00 |
| Food and Beverage | $12,090.23 |
| Travel and Lodging | $3,678.40 |
| Education | $515.75 |
| Honoraria | $260.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $56,436.87 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Novartis Pharmaceuticals Corporation | $1,980.96 | 2020-2025 | |
| Abbvie INC. | $1,875.85 | 2019-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $1,568.00 | 2021-2025 | Ilumya, Winlevi |
| Janssen Biotech, INC. | $1,436.99 | 2020-2025 | Tremfya, Simponi, Stelara |
| E.R. Squibb & Sons, L.L.C. | $1,330.94 | 2022-2025 | Sotyktu |
| Amgen INC. | $1,240.51 | 2019-2025 | Otezla, Otezla, Enbrel |
| Genzyme Corporation | $1,238.65 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,204.42 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $1,015.73 | 2021-2025 | Opzelura |
| Ucb, INC. | $911.26 | 2020-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $851.74 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $637.42 | 2019-2025 | |
| Leo Pharma INC. | $604.83 | 2021-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $558.88 | 2022-2024 | Vtama |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $483.55 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $316.68 | 2020-2024 | Arazlo, Jublia, Cabtreo |
| Sanofi-Aventis U.S. LLC | $171.99 | 2020-2021 | |
| Organon LLC | $144.43 | 2025 | Vtama |
| Genentech USA, INC. | $121.06 | 2021-2025 | Xolair |
| Epi Health, LLC | $99.03 | 2020-2022 | |
| Celgene Corporation | $72.63 | 2019 | |
| Almirall LLC | $72.13 | 2022-2024 | Seysara |
| Dermira, INC. | $58.23 | 2020-2021 | |
| Journey Medical Corporation | $56.13 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $48.26 | 2023 | |
| Revance Therapeutics, INC. | $44.92 | 2024 | Daxxify |
| Botanix Sb INC | $43.15 | 2025 | Sofdra |
| Astrazeneca Pharmaceuticals LP | $43.07 | 2023 | Evusheld |
| Mayne Pharma Commercial LLC | $41.20 | 2023-2025 | |
| Lnhc, INC | $40.29 | 2025 | Zelsuvmi |
| Cipher Pharmaceuticals US LLC | $31.84 | 2025 | Natroba, Spinosad |
| Kyowa Kirin, INC. | $17.52 | 2025 | |
| Vyne Pharmaceuticals INC. | $15.33 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $13.52 | 2021 | |
| Biofrontera INC. | $12.85 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Strata Skin Sciences, INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw German Treyger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.